Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (NASDAQ: MLAB) is described in its public communications as a global leader in the design and manufacture of life science tools and critical quality control solutions. Its news flow reflects this focus, with regular updates related to regulated applications in the pharmaceutical, healthcare, and medical device industries.
Visitors to this MLAB news page can review company-issued press releases covering financial results, divisional performance, and capital structure decisions. Mesa frequently announces quarterly results for its four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics—highlighting revenues, organic and core organic revenues growth, and commentary on factors such as tariffs, foreign exchange, and geographic trends.
The news stream also includes dividend declarations, where the Board of Directors approves a regular quarterly dividend on Mesa’s common stock, along with record and payment dates. In addition, Mesa issues releases about investor conference participation and healthcare conference presentations, providing context for how management communicates with the investment community.
Another recurring theme in Mesa’s news is financing and balance sheet activity, such as the execution of strategic financing plans, use of its credit facility, and repayment or settlement of convertible notes. These items offer insight into how the company manages its capital structure alongside its operating performance.
By following this page, readers can access a chronological view of Mesa’s official announcements, including earnings releases, dividend decisions, conference appearances, and financing updates, all drawn from the company’s own disclosures.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has appointed Shiraz Ladiwala to its Board of Directors as of October 28, 2021. Ladiwala, a former leader at Thermo Fisher Scientific, has extensive experience in corporate strategy and operations with a focus on the Asia/Pacific region. His addition brings the board to eight members, with six being independent. The chairman, John Sullivan, emphasized Ladiwala's international expertise, which is expected to support Mesa's strategic objectives and mission to enhance safety and quality in life sciences.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has successfully completed the acquisition of Agena Biosciences, Inc. This strategic move aims to enhance Mesa's growth in the life sciences tools market, with expectations that over 90% of future revenues will derive from biopharma, medical devices, and healthcare services. Agena is projected to add $63M to $67M in revenue within the first year, with a significant portion expected to be recurring. The acquisition positions Mesa to benefit from high single-digit organic revenue growth and strengthens its global presence.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, set to be paid on December 15, 2021. Shareholders must be on record by November 30, 2021. Mesa is a leading provider of quality control solutions across pharmaceutical, healthcare, and medical device sectors, with products segmented into four divisions aimed at ensuring safety and quality in these industries. The company cautions that future performance may be influenced by various risks including market demand fluctuations and economic uncertainties.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced its acquisition of Agena Bioscience, Inc. for $300 million, expected to close by December 31, 2021. This all-cash transaction will be financed by cash on hand and credit facilities. Agena, known for its molecular diagnostics tools, is projected to add $63-$67 million in revenues in the first year, with approximately 65% being recurring. The acquisition is expected to enhance Mesa's capabilities in clinical genomics, providing innovative solutions for personalized treatment.
Mesa Laboratories reported a strong 1Q22, with revenues increasing 17% year-over-year to $34,920,000. However, operating income fell 13% to $3,123,000. Net income surged 64% to $1,995,000, translating to $0.38 per diluted share. Adjusted operating income rose 12% to $9,136,000, reflecting strong performance in the Sterilization and Disinfection Control segment. The company noted a gross profit percentage decline of 430 bps to 64% overall. CEO Gary Owens expressed optimism about growth opportunities despite economic uncertainties linked to COVID and inflation.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, payable on September 15, 2021, to shareholders of record by the close of business on August 31, 2021. Mesa Labs specializes in quality control solutions across various sectors including pharmaceutical and healthcare. Their mission is to enhance product integrity and safety by offering services through four divisions. The company advises caution as actual results may differ due to risks highlighted in their forward-looking statements.
Mesa Laboratories (NASDAQ:MLAB) reported strong financial results for FY21 and 4Q21, with revenues rising 14% to $133.9 million and 11% to $37.96 million, respectively. Operating income surged 56% for the year and 318% for the quarter, while net income reached $3.27 million, a significant increase of 84% year-over-year. Adjusted operating income also increased 48% to $36.14 million. The company highlighted momentum in its Biopharmaceutical Development division with a 23% organic growth. However, the Instruments division faced challenges with a revenue decline of 15% due to COVID-19 impacts.
Mesa Laboratories (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, set to be paid on June 15, 2021, to shareholders recorded as of May 31, 2021. This decision reflects the company's commitment to returning value to shareholders. Mesa Labs focuses on providing essential quality control solutions across various industries, enhancing product integrity and worker safety.
Mesa Laboratories (NASDAQ:MLAB) reported financial results for 3Q21, revealing an 8% revenue increase to $34,172. Operating income rose significantly to $22 compared to a loss of $(3,255) in 3Q20. Despite this, net loss increased slightly to $(4,542) or $(0.89) per diluted share. Adjusted operating income surged by 162% to $7,461. Excluding unusual items, operating income dropped by 49%. The Sterilization and Disinfection Control division saw 13% growth. However, the Instruments division faced a 10% revenue decline, indicating mixed performance across segments.
Mesa Laboratories (NASDAQ:MLAB) announced a regular quarterly dividend of $0.16 per share, payable on March 15, 2021, to shareholders on record as of February 26, 2021. The company continues to lead in providing critical quality control solutions across various industries, including healthcare and pharmaceuticals. This dividend declaration reflects Mesa Labs' ongoing commitment to rewarding shareholders while maintaining its position as a trusted provider of quality control products and services.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
